Stock Events

Stock Events

Trevi Therapeutics 

$16.79
26
-$1.17-6.51% Friday 20:00
-$0.07-0.4%Friday 21:24After hours

Statistics

Day High
17.08
Day Low
16.76
52W High
20.22
52W Low
6.93
Volume
44,096
Avg. Volume
-
Mkt Cap
2.39B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.13
-0.11
-0.09
-0.08
Expected EPS
-0.131442
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-42.76MNet Income

Analyst Ratings

25.38Average Price Target
The highest estimate is 36.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TRVI. It's not an investment recommendation.
Apple
7
AAPL
Amazon
7
AMZN
Microsoft
6
MSFT
Tesla
6
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.91B
Vertex Pharmaceuticals is a competitor because it also develops treatments for serious diseases, potentially overlapping with Trevi's focus areas.
Biogen
BIIB
Mkt Cap32.03B
Biogen competes in the neurology space, which may intersect with Trevi's therapeutic areas.
Alkermes
ALKS
Mkt Cap8.11B
Alkermes competes in the area of central nervous system diseases, similar to Trevi's focus.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.08B
Acadia Pharmaceuticals targets central nervous system disorders, aligning with Trevi's market.
AMGEN
AMGN
Mkt Cap237.52B
Amgen has a broad portfolio that could compete with Trevi's treatments in overlapping disease areas.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap43.51B
Teva Pharmaceutical Industries has a wide range of products that could compete with Trevi's pipeline.
Jazz Pharmaceuticals
JAZZ
Mkt Cap16.51B
Jazz Pharmaceuticals has a focus on neurological disorders, potentially competing with Trevi.
Novartis
NVS
Mkt Cap301.95B
Novartis offers medications in various therapeutic areas, including those that could compete with Trevi's.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie's broad focus on serious diseases includes areas that may overlap with Trevi's therapeutic targets.

About

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Show more...
CEO
Jennifer L. Good
Employees
34
Country
United States
ISIN
US89532M1018

Listings

XNAS
US
TRVI
BOATS
BOATS
TRVI.BOATS

0 Comments

Share your thoughts

FAQ

What is Trevi Therapeutics stock price today?▼
The current price of TRVI is $16.79 USD — it has decreased by -6.51% in the past 24 hours. Watch Trevi Therapeutics stock price performance more closely on the chart.
What is Trevi Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Trevi Therapeutics stocks are traded under the ticker TRVI.
Is Trevi Therapeutics stock price growing?▼
TRVI stock has fallen by -6.51% compared to the previous week, the month change is a -7.19% fall, over the last year Trevi Therapeutics has showed a +131.43% increase.
What is Trevi Therapeutics market cap?▼
Today Trevi Therapeutics has the market capitalization of 2.39B
When is the next Trevi Therapeutics earnings date?▼
Trevi Therapeutics is going to release the next earnings report on November 11, 2026.
What were Trevi Therapeutics earnings last quarter?▼
TRVI earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.11 USD resulting in a -0.5% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Trevi Therapeutics revenue for the last year?▼
Trevi Therapeutics revenue for the last year amounts to 0 USD.
What is Trevi Therapeutics net income for the last year?▼
TRVI net income for the last year is -42.76M USD.
How many employees does Trevi Therapeutics have?▼
As of August 29, 2026, the company has 34 employees.
In which sector is Trevi Therapeutics located?▼
Trevi Therapeutics operates in the Health & Wellness sector.
When did Trevi Therapeutics complete a stock split?▼
Trevi Therapeutics has not had any recent stock splits.
Where is Trevi Therapeutics headquartered?▼
Trevi Therapeutics is headquartered in NEW HAVEN, United States.